Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Humedics Co-founder Martin Stockmann Awarded with Von-Langenbeck Prize

Published: Tuesday, July 16, 2013
Last Updated: Tuesday, July 16, 2013
Bookmark and Share
Award ceremony at the annual conference of the German Society of Surgery.

Humedics GmbH has announced that PD Dr. Martin Stockmann, co-founder of Humedics and advisor of the management, was awarded with the highest honor of surgery in Germany, the Von-Langenbeck Prize of the German Society of Surgery (Deutsche GesellschaftfürChirurgie).

The Von-Langenbeck Prize is an award for outstanding scientific achievements in the field of surgery. Since 1954, it has been yearly awarded by the German Society of Surgery (Deutsche GesellschaftfürChirurgie).

PD Dr. Martin Stockmann from Charité - Universitätsmedizin Berlin at the Campus Virchow Hospital, Dept. of General, Visceral and Graft Surgery, received the renowned prize for the development and clinical validation of a new technique for determining liver function in surgery - the LiMAx test - and for ten years of research in the field of liver surgery and liver regeneration.

The award ceremony took place at the opening day of the 130th Congress of the German Society of Surgery in Munich. Prof. Dr. Karl-Walter Jauch, president of the society, handed over the prize and congratulated the laureate.

Stockmann said: “This prize is a great honor and pleasure for me. It is an award for more than ten years of research in the field of liver surgery and liver regeneration. I would like to take this opportunity to encourage particularly younger colleagues to engage in research. This needs superior efforts, commitment and - as the motto of this congress - passion, but it pays off.”

The award comes in a phase of the final development of the LiMAx test before regulatory product approval. In January, Humedics announced the start of a clinical phase III study.

The trial with the short title 'Fast-track LiveR' is a prospective, randomized, controlled, multi-centric, phase III study.

The main goal of this study is the early identification of low-risk patients after partial liver resection by the LiMAx test and improvements in patient management based on test results.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More Than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

LiMAx Test Shows Reversibility of Fatty Liver Disease After Obesity Surgery
Clinical study provides evidence for functional liver recovery after weight loss.
Tuesday, September 15, 2015
Humedics Receives ISO 13485 Certification
Milestone for market entry of LiMAx test for liver function diagnostics.
Tuesday, August 11, 2015
Humedics Closes 6.3 Million€ Financing Round
Cash inflow enables for commercialization of the LiMAx test.
Friday, November 14, 2014
Humedics Receives Patent on Method for Quantitative Liver Function Analysis
Patent is a milestone for further commercialization of the LiMAx test.
Tuesday, April 16, 2013
Humedics Starts LiMAx Phase III Trial on Liver Function Analysis for Severe Liver Surgery
First patients being included directly after study initiation in Berlin and Jena.
Monday, March 04, 2013
Humedics Appoints Erwin de Buijzer as Managing Director for Marketing and Sales
Erwin de Buijzer support further development and strategic positioning of the company.
Monday, May 07, 2012
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
The MaxSignal Colistin ELISA Test Kit from Bioo Scientific
Kit can help prevent the antibiotic apocalypse by keeping last resort drugs out of the food supply.
"Good" Mozzie Virus Might Hold Key to Fighting Human Disease
Australian scientists have discovered a new virus carried by one of the country’s most common pest mosquitoes.
Non-Disease Proteins Kill Brain Cells
Scientists at the forefront of cutting-edge research into neurodegenerative diseases such as Alzheimer’s and Parkinson’s have shown that the mere presence of protein aggregates may be as important as their form and identity in inducing cell death in brain tissue.
Closing the Loop on an HIV Escape Mechanism
Research team finds that protein motions regulate virus infectivity.
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Potential Treatment for Life-Threatening Viral Infections Revealed
The findings point to new therapies for Dengue, West Nile and Ebola.
World’s First Therapeutic Venom Database
Open-source library describes nearly 43,000 effects on the human body.
Biologists Induce Flatworms to Grow Heads and Brains of Other Species
Findings shed light on role of a new kind of epigenetic signaling in evolution, could yield clues for understanding birth defects and regeneration.
Fat Cells Originating from Bone Marrow Found in Humans
Cells could contribute to diabetes, heart disease.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos